In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...

Like its predecessor, “Wicked: For Good” more than doubles the runtime of Act II of the Broadway musical that inspired it. But unlike the first “Wicked” film, the sequel makes big additions to the ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Horror Movies Five Nights at Freddy's 2 review: "We have waited two years for a Five Nights at Freddy's 1.5" Horror Movies The Long Walk is one of the best Stephen King adaptations of all time – and ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

Diebold Nixdorf isn't as well-known as BigBear.ai, but it could have better growth prospects. Recursion Pharmaceuticals' AI drug discovery gives it a shot at growing larger than BigBear.ai. BigBear.ai ...

It can be easy to confuse the two, but there’s a difference, and it has to do with your internet speeds. Joe Supan is a senior writer for CNET covering home technology, broadband, and moving. Prior to ...